Search results
Results from the WOW.Com Content Network
Serious side effects may include anaphylaxis, liver problems, depression, and muscle breakdown. [4] [5] Use in pregnancy and breastfeeding is of unclear safety. [10] Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic ...
It is a combination of ezetimibe (known as Zetia in the United States) and the statin drug simvastatin (known as Zocor in the US). Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [1] [3] It is a combination of bempedoic acid and ezetimibe. [1] [2] The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation. [2]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
Skin cancer is the most commonly diagnosed form of cancer in humans. [11] [12] [13] There are three main types of skin cancers: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. [1] The first two, along with a number of less common skin cancers, are known as nonmelanoma skin cancer (NMSC).
Nausea and vomiting are two of the most feared cancer treatment-related side-effects for people with cancer and their families. In 1983, Coates et al. found that people receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. [ 98 ]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The investigators report that adding ezetimibe to the statin drug simvastatin reduced LDL-C by an additional 15-mg/dL, relative risk of cardiovascular events by 6.4%, and relative risk of cardiovascular death, myocardial infarction (heart attack), or stroke by 10% relative to simvastatin alone; specifically, 34.7% of patients given simvastatin ...